EAN 2025 | The need for standardized protocols to diagnose alpha-synucleopathies
Anastasia Bougea, PhD, National and Kapodistrian University of Athens, Athens, Greece, highlights the need for standardized protocols to study alpha-synucleopathies. She emphasizes the potential of advanced technologies, such as next-generation sequencing and liquid biopsies, to integrate biomarkers into clinical practice for Parkinsonian syndromes. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The lack of standardized protocols for studying alpha-synucleopathies is a very important limitation. So again, one time I want to highlight that advanced technologies such as next-generation sequencing and liquid biopsies are expected to become the weapons that we are going to overcome these barriers, these limitations, to incorporate them in a normal clinical setting as diagnostic tools...
The lack of standardized protocols for studying alpha-synucleopathies is a very important limitation. So again, one time I want to highlight that advanced technologies such as next-generation sequencing and liquid biopsies are expected to become the weapons that we are going to overcome these barriers, these limitations, to incorporate them in a normal clinical setting as diagnostic tools. And the diagnostic industry should shift towards a more integrated approach over the course of the next five or ten years. So, together with the artificial intelligence tools, they are going to help to make the biomarkers the tools for clinical practice for Parkinsonian syndromes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
